{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:46:27Z","timestamp":1791927987226,"version":"4.3.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01300-6","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:03:19Z","timestamp":1791867799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed Drug Hypersensitivity: Mechanistic Advances and Emerging Therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Ahmed","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Runyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Alvarez-Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70480","author":"MJ Torres","year":"2026","unstructured":"Torres MJ, Mayorga C, Phillips EJ, Ariza A, Barbaud A, Bonadonna P, et al. Nomenclature on immune-mediated drug reactions: an EAACI position paper. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70480.","journal-title":"Allergy"},{"issue":"8","key":"1300_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","volume":"139","author":"WJ Pichler","year":"2003","unstructured":"Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683\u201393.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jaip.2024.02.019","volume":"12","author":"S Alvarez-Arango","year":"2024","unstructured":"Alvarez-Arango S, Kumar M, Chow TG, Sabato V. Non-IgE-mediated immediate drug-induced hypersensitivity reactions. J Allergy Clin Immunol Pract. 2024;12(5):1109\u201319.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1016\/j.jaip.2023.08.009","volume":"11","author":"F Bassir","year":"2023","unstructured":"Bassir F, Alvarez-Arango S, Kroshinsky D, Phillips E, Ezeofor AJ, Samarakoon U, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical presentation and outcomes in people of color. J Allergy Clin Immunol Pract. 2023;11(11):3537\u201340.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","volume":"13","author":"T Tempark","year":"2022","unstructured":"Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C. Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol. 2022;13:832048.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1300_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","volume":"52","author":"T Hunziker","year":"1997","unstructured":"Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388\u201393.","journal-title":"Allergy"},{"issue":"7","key":"1300_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.arcmed.2006.03.010","volume":"37","author":"A Hernandez-Salazar","year":"2006","unstructured":"Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899\u2013902.","journal-title":"Arch Med Res."},{"issue":"2","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jaci.2022.12.005","volume":"151","author":"A Gibson","year":"2023","unstructured":"Gibson A, Deshpande P, Campbell CN, Krantz MS, Mukherjee E, Mockenhaupt M, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol. 2023;151(2):289-300 e4.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1300_CR9","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jaip.2026.01.003","volume":"14","author":"LY Loo","year":"2026","unstructured":"Loo LY, Ngiam NHW, Sultana R, Lee HY. Generalized bullous fixed drug eruption: a systematic review. J Allergy Clin Immunol Pract. 2026;14(3):668\u201375.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","volume":"10","author":"N Hama","year":"2022","unstructured":"Hama N, Abe R, Gibson A, Phillips EJ. Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract. 2022;10(5):1155-67 e5.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"1300_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jaip.2026.02.008","volume":"14","author":"S Alvarez-Arango","year":"2026","unstructured":"Alvarez-Arango S, Konvinse KC, Pujar M, Salciccioli IP, Bland CM, Blumenthal KG. Redefining diagnostic and management approaches to vancomycin adverse drug reactions. J Allergy Clin Immunol Pract. 2026;14(5):1034\u201347.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/ddg.15466","volume":"22","author":"A Glassner","year":"2024","unstructured":"Glassner A, Wessollek K, Yazdi AS, Sachs B. In vitro diagnostics of drug allergies. J Dtsch Dermatol Ges. 2024;22(11):1529\u201340.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","volume":"150","author":"DA Khan","year":"2022","unstructured":"Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333\u201393.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1300_CR14","first-page":"34","volume":"24","author":"R Heuer","year":"2026","unstructured":"Heuer R, Paulmann M, Mockenhaupt M, Nast A. Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis): a systematic review and meta-analysis. JDDG J Dtsch Dermatol Ges. 2026;24(1):34\u201342.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"6","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","volume":"153","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514\u201322.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1300_CR16","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1038\/s41467-024-52990-3","volume":"15","author":"A Gibson","year":"2024","unstructured":"Gibson A, Ram R, Gangula R, Li Y, Mukherjee E, Palubinsky AM, et al. Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Commun. 2024;15(1):8722.","journal-title":"Nat Commun"},{"issue":"8040","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","volume":"635","author":"TM Nordmann","year":"2024","unstructured":"Nordmann TM, Anderton H, Hasegawa A, Schweizer L, Zhang P, Stadler PC, et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. Nature. 2024;635(8040):1001\u20139.","journal-title":"Nature"},{"issue":"11","key":"1300_CR18","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.4049\/jimmunol.1700209","volume":"198","author":"X Meng","year":"2017","unstructured":"Meng X, Al-Attar Z, Yaseen FS, Jenkins R, Earnshaw C, Whitaker P, et al. Definition of the nature and hapten threshold of the beta-lactam antigen required for T cell activation in vitro and in patients. J Immunol. 2017;198(11):4217\u201327.","journal-title":"J Immunol"},{"issue":"4","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","volume":"2","author":"WJ Pichler","year":"2002","unstructured":"Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301\u20135.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"25","key":"1300_CR20","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.1073\/pnas.1207934109","volume":"109","author":"DA Ostrov","year":"2012","unstructured":"Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109(25):9959\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7404","key":"1300_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nature11147","volume":"486","author":"PT Illing","year":"2012","unstructured":"Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486(7404):554\u20138.","journal-title":"Nature"},{"issue":"2","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5415\/apallergy.2016.6.2.77","volume":"6","author":"J Yun","year":"2016","unstructured":"Yun J, Cai F, Lee FJ, Pichler WJ. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pac Allergy. 2016;6(2):77\u201389.","journal-title":"Asia Pac Allergy"},{"key":"1300_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev-pharmtox-010818-021818","volume":"59","author":"JH Karnes","year":"2019","unstructured":"Karnes JH, Miller MA, White KD, Konvinse KC, Pavlos RK, Redwood AJ, et al. Applications of Immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions. Annu Rev Pharmacol Toxicol. 2019;59:463\u201386.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6982","key":"1300_CR24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.","journal-title":"Nature"},{"issue":"11","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"1300_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"AM Martin","year":"2005","unstructured":"Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19(1):97\u20139.","journal-title":"AIDS"},{"issue":"1","key":"1300_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/FPC.0000000000000510","volume":"34","author":"VL Bui","year":"2024","unstructured":"Bui VL, Alvarez-Arango S, Stevenson JM. Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated? Pharmacogenet Genomics. 2024;34(1):16\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"1300_CR29","doi-asserted-by":"publisher","first-page":"886377","DOI":"10.3389\/fphar.2022.886377","volume":"13","author":"CW Wang","year":"2022","unstructured":"Wang CW, Preclaro IAC, Lin WH, Chung WH. An updated review of genetic associations with severe adverse drug reactions: translation and implementation of pharmacogenomic testing in clinical practice. Front Pharmacol. 2022;13:886377.","journal-title":"Front Pharmacol"},{"issue":"46","key":"1300_CR30","doi-asserted-by":"publisher","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","volume":"2","author":"D Picard","year":"2010","unstructured":"Picard D, Janela B, Descamps V, D\u2019Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46):46ra62.","journal-title":"Sci Transl Med."},{"issue":"2","key":"1300_CR31","doi-asserted-by":"publisher","first-page":"e0117160","DOI":"10.1371\/journal.pone.0117160","volume":"10","author":"A Lucas","year":"2015","unstructured":"Lucas A, Lucas M, Strhyn A, Keane NM, McKinnon E, Pavlos R, et al. Abacavir-reactive memory T cells are present in drug naive individuals. PLoS ONE. 2015;10(2):e0117160.","journal-title":"PLoS ONE"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"654190","DOI":"10.3389\/fimmu.2021.654190","volume":"12","author":"EM Schunkert","year":"2021","unstructured":"Schunkert EM, Shah PN, Divito SJ. Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions. Front Immunol. 2021;12:654190.","journal-title":"Front Immunol"},{"key":"1300_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178253","author":"PN Shah","year":"2024","unstructured":"Shah PN, Romar GA, Manukyan A, Ko WC, Hsieh PC, Velasquez GA, et al. Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI178253.","journal-title":"J Clin Invest"},{"issue":"3","key":"1300_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.alit.2025.05.002","volume":"74","author":"J Justice","year":"2025","unstructured":"Justice J, Mukherjee E, Martin-Pozo M, Phillips E. Updates in the pathogenesis of SJS\/TEN. Allergol Int. 2025;74(3):361\u201371.","journal-title":"Allergol Int"},{"issue":"12","key":"1300_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343\u201350.","journal-title":"Nat Med"},{"issue":"245","key":"1300_CR36","doi-asserted-by":"publisher","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","volume":"6","author":"N Saito","year":"2014","unstructured":"Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med. 2014;6(245):245ra95.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1300_CR37","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1038\/s41467-025-63744-0","volume":"16","author":"H Kimura","year":"2025","unstructured":"Kimura H, Hasegawa A, Nishiguchi T, Nguyen HH, Eguchi M, Kinoshita M, et al. Inhibition of formyl peptide receptor-1-mediated cell death as a therapy for lethal cutaneous drug reactions in preclinical models. Nat Commun. 2025;16(1):8708.","journal-title":"Nat Commun"},{"issue":"7","key":"1300_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"1300_CR39","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","volume":"139","author":"B Meier-Schiesser","year":"2019","unstructured":"Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, et al. Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis. J Invest Dermatol. 2019;139(4):848\u201358.","journal-title":"J Invest Dermatol"},{"key":"1300_CR40","doi-asserted-by":"publisher","first-page":"1187937","DOI":"10.3389\/fmed.2023.1187937","volume":"10","author":"CB Chen","year":"2023","unstructured":"Chen CB, Hung WK, Wang CW, Lee CC, Hung SI, Chung WH. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med (Lausanne). 2023;10:1187937.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1300_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"K Ogawa","year":"2013","unstructured":"Ogawa K, Morito H, Hasegawa A, Daikoku N, Miyagawa F, Okazaki A, et al. Identification of thymus and activation-regulated chemokine (TARC\/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)\/drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci. 2013;69(1):38\u201343.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"1300_CR42","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/ced\/llag072","volume":"51","author":"W Liu","year":"2026","unstructured":"Liu W, Wang Y, Wang J, Xu H, Shen X, Zheng J, et al. Janus kinase 1 and 1\/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series. Clin Exp Dermatol. 2026;51(6):1076\u201382.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"1300_CR43","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1093\/rheumatology\/keaf356","volume":"64","author":"D Nagra","year":"2025","unstructured":"Nagra D, Song K, Odia J, Wincup C, Mahto A, Rosa C, et al. The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature. Rheumatology (Oxford). 2025;64(11):5641\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1300_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)\u2013a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113\u20139.","journal-title":"J Cutan Pathol"},{"key":"1300_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081214","author":"L Feldmeyer","year":"2016","unstructured":"Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17081214.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1300_CR46","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/jid.2013.44","volume":"133","author":"AA Navarini","year":"2013","unstructured":"Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, et al. Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol. 2013;133(7):1904\u20137.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1300_CR47","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.jacig.2025.100426","volume":"4","author":"EM Mukherjee","year":"2025","unstructured":"Mukherjee EM, Gibson A, Krantz MS, Gangula R, Palubinsky AM, Boyd AS, et al. Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin. J Allergy Clin Immunol Glob. 2025;4(2):100426.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"1","key":"1300_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","volume":"144","author":"KC Konvinse","year":"2019","unstructured":"Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1300_CR49","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1172\/JCI12118","volume":"107","author":"M Britschgi","year":"2001","unstructured":"Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 2001;107(11):1433\u201341.","journal-title":"J Clin Invest"},{"issue":"6","key":"1300_CR50","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jaci.2025.01.046","volume":"155","author":"T Benezeder","year":"2025","unstructured":"Benezeder T, Bordag N, Woltsche J, Falkensteiner K, Graier T, Schadelbauer E, et al. IL-36-driven pustulosis: transcriptomic signatures match between generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP). J Allergy Clin Immunol. 2025;155(6):1913\u201327.","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"1300_CR51","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"key":"1300_CR52","doi-asserted-by":"publisher","first-page":"adv41311","DOI":"10.2340\/actadv.v104.41311","volume":"104","author":"G Russo","year":"2024","unstructured":"Russo G, Dumont S, Menzinger S, Pastor D, Toutous Trellu L, Kaya G, et al. Severe acute generalized exanthematous pustulosis successfully treated by spesolimab. Acta Derm Venereol. 2024;104:adv41311.","journal-title":"Acta Derm Venereol"},{"key":"1300_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179344","author":"M Blaess","year":"2024","unstructured":"Blaess M, Csuk R, Schatzl T, Deigner HP. Elongation of very long-chain fatty acids (ELOVL) in atopic dermatitis and the cutaneous adverse effect AGEP of drugs. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25179344.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1300_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149\u201353.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1300_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1300_CR56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2020.04.020","volume":"84","author":"LL Wang","year":"2021","unstructured":"Wang LL, Noe MH, Micheletti RG. Long-term sequelae from Stevens-Johnson syndrome\/toxic epidermal necrolysis in a large retrospective cohort. J Am Acad Dermatol. 2021;84(3):784\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1300_CR57","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"CW Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985\u201396.","journal-title":"J Clin Invest"},{"issue":"5","key":"1300_CR58","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu CW, Chen CB, Wang CW, Chen WT, Cheng B, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. J Allergy Clin Immunol Pract. 2022;10(5):1295-304 e6.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1300_CR59","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1300_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","volume":"68","author":"YC Chen","year":"2013","unstructured":"Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1300_CR61","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134\u201343.","journal-title":"N Engl J Med"},{"issue":"17","key":"1300_CR62","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","volume":"369","author":"FR Zhang","year":"2013","unstructured":"Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620\u20138.","journal-title":"N Engl J Med"},{"issue":"9","key":"1300_CR63","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cix096","volume":"64","author":"M Thomas","year":"2017","unstructured":"Thomas M, Hopkins C, Duffy E, Lee D, Loulergue P, Ripamonti D, et al. Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clin Infect Dis. 2017;64(9):1198\u2013203.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1300_CR64","doi-asserted-by":"publisher","first-page":"AB428","DOI":"10.1016\/j.jaci.2025.12.953","volume":"157","author":"MGR Krantz","year":"2026","unstructured":"Krantz MGR, Yu A, Ramirez-Valdez E, Wang L, Blackley S, Zhou L, et al. HLA-A*32:01 carriage is associated with lamotrigine-induced drug reaction with eosinophilia and systemic symptoms in a US cohort. J Allergy Clin Immunol. 2026;157(2):AB428.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1300_CR65","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, Prahalad S, Canna S, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81(3):406\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1300_CR66","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jtct.2026.02.020","volume":"32","author":"VBC Saper","year":"2026","unstructured":"Saper VBC, Nguyen K, Davis KL, Ramakrishna S, Moon J, et al. Linking HLA-DRB1*15 to severe dress-like inflammatory toxicities following tocilizumab after CAR-T therapy. Transplant Cell Ther. 2026;32(3):S5.","journal-title":"Transplant Cell Ther."},{"issue":"4","key":"1300_CR67","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/12034754231177590","volume":"27","author":"H Zhu","year":"2023","unstructured":"Zhu H, Ren V. Immunopathogenic insights on preferential human herpesvirus-6 reactivation in drug rash with eosinophilia and systemic symptoms: a scoping review. J Cutan Med Surg. 2023;27(4):388\u201398.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1300_CR68","first-page":"301","volume":"137","author":"V Descamps","year":"2001","unstructured":"Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137(3):301\u20134.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1300_CR69","doi-asserted-by":"publisher","first-page":"28492","DOI":"10.1038\/s41598-024-69054-7","volume":"14","author":"LCE Chan","year":"2024","unstructured":"Chan LCE, Sultana R, Choo KJL, Yeo YW, Pang SM, Lee HY. Viral reactivation and clinical outcomes in drug reaction with eosinophilia and systemic symptoms (DRESS). Sci Rep. 2024;14(1):28492.","journal-title":"Sci Rep"},{"key":"1300_CR70","doi-asserted-by":"publisher","first-page":"1134178","DOI":"10.3389\/fimmu.2023.1134178","volume":"14","author":"L Rubin","year":"2023","unstructured":"Rubin L, Talmon A, Ribak Y, Kessler A, Martin Y, Haran TK, et al. Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Front Immunol. 2023;14:1134178.","journal-title":"Front Immunol"},{"issue":"6","key":"1300_CR71","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamadermatol.2025.0441","volume":"161","author":"B Hijaz","year":"2025","unstructured":"Hijaz B, Nambudiri VE, Imadojemu S. IL-5 Inhibitor treatment in drug reaction with eosinophilia and systemic symptoms. JAMA Dermatol. 2025;161(6):661\u20133.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1300_CR72","first-page":"e86932","volume":"17","author":"KR Ross","year":"2025","unstructured":"Ross KR, Horesh E, Fang MM, Keller JJ. Benralizumab in corticosteroid-refractory drug reaction with eosinophilia and systemic symptoms: a case report. Cureus. 2025;17(6):e86932.","journal-title":"Cureus"},{"key":"1300_CR73","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2022.12.021","volume":"34","author":"E Corona-Rodarte","year":"2023","unstructured":"Corona-Rodarte E, Torres-Guillen VM, Teran-De-la-Sancha K, Barrera-Godinez A, Gatica-Torres M. Successful management with ganciclovir of drug reaction with eosinophilia and systemic symptoms secondary to antituberculous drugs associated to human herpesvirus-6 reactivation. JAAD Case Rep. 2023;34:90\u20133.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"1300_CR74","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0091-6749(03)01624-5","volume":"112","author":"Y Teraki","year":"2003","unstructured":"Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609\u201315.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1300_CR75","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0002-9440(10)64410-0","volume":"161","author":"Y Mizukawa","year":"2002","unstructured":"Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161(4):1337\u201347.","journal-title":"Am J Pathol"},{"issue":"6","key":"1300_CR76","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jid.2022.11.022","volume":"143","author":"Y Matsumura","year":"2023","unstructured":"Matsumura Y, Watanabe R, Koguchi-Yoshioka H, Kume M, Nakai S, Furuta J, et al. Possible plasticity of cytotoxic resident memory T cells in fixed drug eruption. J Invest Dermatol. 2023;143(6):1097-100 e8.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1300_CR77","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2013.11.015","volume":"70","author":"YT Cho","year":"2014","unstructured":"Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome\/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014;70(3):539\u201348.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1300_CR78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.12788\/cutis.1071","volume":"114","author":"AS Bang","year":"2024","unstructured":"Bang AS, Blank NR, Harp J. Distinguishing generalized bullous fixed drug eruption from SJS\/TEN: a retrospective study on clinical and demographic features. Cutis. 2024;114(2):48\u20139.","journal-title":"Cutis"},{"issue":"4","key":"1300_CR79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4103\/ijd.IJD_481_17","volume":"63","author":"R Jhaj","year":"2018","unstructured":"Jhaj R, Chaudhary D, Asati D, Sadasivam B. Fixed-drug eruptions: what can we Learn from a Case Series? Indian J Dermatol. 2018;63(4):332\u20137.","journal-title":"Indian J Dermatol"},{"issue":"50","key":"1300_CR80","doi-asserted-by":"publisher","first-page":"e46293","DOI":"10.1097\/MD.0000000000046293","volume":"104","author":"J Guo","year":"2025","unstructured":"Guo J, Tang Y, Yue Q, Yu H. A real-world pharmacovigilance study of FDA adverse event reporting system events for cefazolin. Medicine (Baltimore). 2025;104(50):e46293.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1300_CR81","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.mcna.2010.04.001","volume":"94","author":"AJ Bircher","year":"2010","unstructured":"Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am. 2010;94(4):711-25,x.","journal-title":"Med Clin North Am."},{"issue":"9","key":"1300_CR82","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1046\/j.1440-1754.2003.00267.x","volume":"39","author":"BA King","year":"2003","unstructured":"King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health. 2003;39(9):677\u201381.","journal-title":"J Paediatr Child Health"},{"issue":"5\u20136","key":"1300_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.0105-1873.2004.00445.x","volume":"51","author":"P Hausermann","year":"2004","unstructured":"Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5\u20136):297\u2013310.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"1300_CR84","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","volume":"9","author":"T Shiohara","year":"2009","unstructured":"Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316\u201321.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"1300_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bjornsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1300_CR86","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe\u2019er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816\u20139.","journal-title":"Nat Genet"},{"issue":"3","key":"1300_CR87","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1021\/acs.chemrestox.5c00530","volume":"39","author":"E Saville","year":"2026","unstructured":"Saville E, Wells G, Farrell L, Naisbitt DJ, Meng X. Insights into the Biochemical and Immune Mechanisms in Drug-Induced Liver Injury Pathogenesis. Chem Res Toxicol. 2026;39(3):267\u201382.","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"1300_CR88","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nrneph.2010.71","volume":"6","author":"MA Perazella","year":"2010","unstructured":"Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"1300_CR89","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.ki.5002776","volume":"73","author":"E Gonzalez","year":"2008","unstructured":"Gonzalez E, Gutierrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940\u20136.","journal-title":"Kidney Int"},{"issue":"10","key":"1300_CR90","doi-asserted-by":"publisher","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","volume":"4","author":"DG Moledina","year":"2019","unstructured":"Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, et al. Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight. 2019;4(10):e127456.","journal-title":"JCI Insight."},{"key":"1300_CR91","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.31.685702","author":"Q Qin","year":"2025","unstructured":"Qin Q, Ostendorf L, Wells SL, Gao C, Tran M, Alikhan FM, et al. Spatial transcriptomics identify T cell-driven mechanisms of kidney damage in immune checkpoint inhibitor-associated acute interstitial nephritis. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.10.31.685702.","journal-title":"bioRxiv"},{"key":"1300_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178813","author":"G Xi","year":"2025","unstructured":"Xi G, McLnnis EA, Lardinois O, Hu P, Poulton JS, Free ME, et al. Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitis. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI178813.","journal-title":"J Clin Invest"},{"issue":"1","key":"1300_CR93","doi-asserted-by":"publisher","first-page":"103924","DOI":"10.1016\/j.autrev.2025.103924","volume":"25","author":"JW Cohen Tervaert","year":"2026","unstructured":"Cohen Tervaert JW. Drug- and vaccine induced ANCA-associated vasculitis: an overview. Autoimmun Rev. 2026;25(1):103924.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1300_CR94","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","volume":"30","author":"Y He","year":"2018","unstructured":"He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"1300_CR95","unstructured":"Saliba F, Blum MA, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. StatPearls. Treasure Island (FL)2026."},{"issue":"2","key":"1300_CR96","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.semarthrit.2018.01.005","volume":"48","author":"B Kumar","year":"2018","unstructured":"Kumar B, Strouse J, Swee M, Lenert P, Suneja M. Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018;48(2):283\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"1300_CR97","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjd.12125","volume":"168","author":"A Barbaud","year":"2013","unstructured":"Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555\u201362.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1300_CR98","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/all.12142","volume":"68","author":"K Brockow","year":"2013","unstructured":"Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs \u2013 an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702\u201312.","journal-title":"Allergy"},{"issue":"10","key":"1300_CR99","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1016\/j.jaip.2024.05.045","volume":"12","author":"M Porter","year":"2024","unstructured":"Porter M, Smith R, Teixeira N, Thwala B, Choshi P, Phillips EJ, et al. First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting. J Allergy Clin Immunol Pract. 2024;12(10):2798-808 e12.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"9","key":"1300_CR100","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/cea.12145","volume":"43","author":"G Porebski","year":"2013","unstructured":"Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027\u201337.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1300_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","volume":"65","author":"Y Fujita","year":"2011","unstructured":"Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, et al. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2011;65(1):65\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1300_CR102","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/all.12886","volume":"71","author":"C Mayorga","year":"2016","unstructured":"Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103\u201334.","journal-title":"Allergy"},{"issue":"3","key":"1300_CR103","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/all.15957","volume":"79","author":"C Mayorga","year":"2024","unstructured":"Mayorga C, Celik GE, Pascal M, Hoffmann HJ, Eberlein B, Torres MJ, et al. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper. Allergy. 2024;79(3):580\u2013600.","journal-title":"Allergy"},{"key":"1300_CR104","doi-asserted-by":"publisher","first-page":"1532775","DOI":"10.3389\/falgy.2025.1532775","volume":"6","author":"A Glassner","year":"2025","unstructured":"Glassner A, Dubrall D, Wurpts G, Deck P, Weindl G, Heubach CA, et al. Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions. Front Allergy. 2025;6:1532775.","journal-title":"Front Allergy"},{"issue":"2","key":"1300_CR105","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"1300_CR106","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.17039","volume":"51","author":"TK Satoh","year":"2024","unstructured":"Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE. Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications. J Dermatol. 2024;51(1):3\u201311.","journal-title":"J Dermatol"},{"key":"1300_CR107","doi-asserted-by":"publisher","first-page":"952099","DOI":"10.3389\/fimmu.2022.952099","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Yu Y, Zhang M, Tang Y, Wu D, Wang S, et al. Association between germ-line HLA and immune-related adverse events. Front Immunol. 2022;13:952099.","journal-title":"Front Immunol"},{"issue":"7","key":"1300_CR108","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","volume":"30","author":"YS Teng","year":"2023","unstructured":"Teng YS, Yu S. Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 2023;30(7):6805\u201319.","journal-title":"Curr Oncol"},{"key":"1300_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J Immunother Cancer"},{"issue":"36","key":"1300_CR110","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1300_CR111","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44272-025-00043-1","volume":"4","author":"YHJ Sun","year":"2025","unstructured":"Sun YHJ, Hu F, Xue R, Chang X, Cheng L, et al. Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors. Clin Cancer Bull. 2025;4(1):16.","journal-title":"Clin Cancer Bull."}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01300-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:18Z","timestamp":1791925398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01300-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01300-6","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"26 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}